Alexandria T M Lee (Alexandria Lee)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 12

Top Topics

Interstitial Lung Disease

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Lung Cancer (Auckland, N.Z.)

This page only lists publications with an associated author ORCID identifier.

Publications

Alexandria T M Lee, Sai-Hong Ignatius Ou
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Misako Nagasaka
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Shannon S Zhang, Alexandria T M Lee, Misako Nagasaka
CodeBreak 200: Sotorasib Has Not Broken the KRAS G12C Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Misako Nagasaka
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer (Auckland, N.Z.) 14 (2023)
Shannon S Zhang, Alexandria T M Lee, Misako Nagasaka
CodeBreak 200: Sotorasib Has Not Broken the KRAS G12C Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)